Single-Use Technology for Biopharmaceuticals Market Size, Share & Industry Analysis, By Product Type (Equipment & Systems [Bioreactors, Chromatography Systems, and Mixers] and Consumables [Connectors, Tubing, and Filters]), By Workflow (Upstream Processing, Downstream Processing, and Ancillary Operations), By Biopharmaceutical Modality (Monoclonal Antibodies, Recombinant Proteins, Vaccines, and Biosimilars), By Scale (Clinical and Commercial), By End User (Pharmaceutical & Biopharmaceutical Companies, CDMOs & CROs, and Academic & Research Institutes), and Regional Forecast, 2026-2034

The global single-use technology for biopharmaceuticals market size was valued at USD 18.44 billion in 2025. The market is projected to grow from USD 20.05 billion in 2026 to USD 41.17 billion by 2034, exhibiting a CAGR of 9.4% during the forecast period.

Single-use Technology (SUT) in biopharmaceuticals uses disposable plastic equipment instead of traditional stainless steel. These pre-sterilized components are used once and then discarded, eliminating the need for complex cleaning and sterilization. The rapid expansion of cell and gene therapy manufacturing is significantly driving the adoption of single-use technologies across the global biopharmaceutical industry. Moreover, the growing preference for outsourcing biopharmaceutical manufacturing to Contract Development and Manufacturing Organizations (CDMOs) is emerging as a major driver for the market.

Leading companies, including Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, and Repligen Corporation maintain strong market positions through continuous product innovation, strategic acquisitions, manufacturing capacity expansion, and comprehensive portfolios spanning upstream and downstream bioprocessing applications.

Download Free sample to learn more about this report.

SINGLE-USE TECHNOLOGY FOR BIOPHARMACEUTICALS MARKET TRENDS

Increasing Integration of Automation and Digital Technologies in Single-Use Bioprocessing is a Key Market Trend

The integration of automation, digitalization, and smart manufacturing technologies into single-use bioprocessing systems has emerged as a key trend shaping the global market. As biologics manufacturing becomes increasingly complex, pharmaceutical and biotechnology companies are adopting digitally connected single-use platforms to improve process control, operational efficiency, and product quality. Modern single-use systems are being equipped with advanced sensors, real-time monitoring technologies, Process Analytical Technology (PAT), automated control systems, and data analytics software that enable continuous monitoring of critical process parameters such as pH, dissolved oxygen, temperature, pressure, and flow rates. These technologies support data-driven decision-making, reduce operator intervention, improve batch consistency, and facilitate predictive process optimization.

The growing adoption of Industry 4.0 principles is further accelerating the deployment of automated single-use manufacturing platforms across upstream and downstream bioprocessing operations. Manufacturers are increasingly integrating cloud-based process management systems, digital twins, Artificial Intelligence (AI), Machine Learning (ML), and advanced Manufacturing Execution Systems (MES) to enhance production efficiency and minimize operational risks.

Automated single-use bioreactors, filtration systems, mixing platforms, and fluid management assemblies enable rapid process adjustments while maintaining closed-system manufacturing environments that reduce contamination risks. Furthermore, increasing investments in continuous bioprocessing and flexible manufacturing facilities are encouraging technology providers to develop intelligent single-use solutions capable of seamless integration with automated production workflows. Leading market participants are also collaborating with software providers and automation companies to deliver end-to-end digital bioprocessing platforms that improve traceability, regulatory compliance, and manufacturing scalability.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Demand for Biologics and Biosimilars is Driving Market Growth

The increasing demand for biologics and biosimilars is one of the primary factors driving the global single-use technology for biopharmaceuticals market growth. Biologics, including monoclonal antibodies, recombinant proteins, vaccines, blood-derived products, and advanced biologic therapies, have become essential treatment options for chronic diseases such as cancer, autoimmune disorders, diabetes, and rare genetic conditions. As pharmaceutical companies continue to expand their biologics pipelines, manufacturers require flexible and efficient production systems capable of supporting both clinical-scale and commercial-scale manufacturing.

• For instance, in May 2026, Amgen announced an additional USD 300 million investment to expand its U.S. manufacturing network, bringing its total commitment over the past year to nearly USD 2 billion. The investment enhances biologics production capacity, strengthens supply chain resilience, and advances next-generation manufacturing technologies at its Puerto Rico facility.

Single-use technologies have emerged as a preferred alternative to conventional stainless-steel systems, as they eliminate cleaning validation, reduce the risk of cross-contamination, minimize water and energy consumption, and shorten production turnaround times. These advantages enable manufacturers to improve operational efficiency while reducing capital investment and operating costs. In addition, the growing commercialization of biosimilars is increasing the need for cost-effective manufacturing platforms that can rapidly adapt to varying production volumes and multiple product campaigns. Single-use bioreactors, disposable filtration systems, fluid management assemblies, and bioprocess containers enable manufacturers to accelerate facility setup, reduce downtime between production batches, and improve manufacturing flexibility.

• For instance, in June 2026, Sandoz inaugurated a USD 99 million state-of-the-art biosimilar development center in Ljubljana, Slovenia. The fully integrated facility strengthens in-house biosimilar development capabilities, accelerates pipeline advancement, and supports the company's strategy to capitalize on biosimilars.

Regulatory agencies have also encouraged the adoption of modern manufacturing technologies that improve product quality, sterility assurance, and process consistency, further supporting the deployment of disposable bioprocessing systems. Moreover, pharmaceutical companies are increasingly investing in new biologics manufacturing facilities across North America, Europe, and Asia Pacific, many of which are designed around single-use manufacturing platforms.

MARKET RESTRAINTS

Considerable Concerns Related to Extractables, Leachables, and Regulatory Compliance to Deter Market Growth

Concerns regarding extractables, leachables, and regulatory compliance remain one of the key restraints affecting the market growth. Single-use bioprocessing systems are primarily manufactured using polymer-based materials, including plastic films, tubing, connectors, filters, and storage bags. Under various manufacturing conditions, these materials may release trace chemical compounds, commonly referred to as extractables and leachables, into the process stream. Such compounds have the potential to interact with biologics, vaccines, recombinant proteins, and cell and gene therapy products, potentially affecting product quality, stability, safety, and therapeutic efficacy. As a result, biopharmaceutical manufacturers are required to conduct comprehensive Extractables and Leachables (E&L) studies before implementing single-use systems in commercial manufacturing.

• For instance, in August 2025, the International Council for Harmonisation (ICH) released the draft Q3E guideline for extractables and leachables, introducing harmonized risk assessment and control requirements for manufacturing systems, including single-use technologies, to strengthen product quality, safety, and regulatory compliance.

The qualification process involves extensive material compatibility assessments, toxicological evaluations, process validation, and regulatory documentation to demonstrate product safety and compliance with global regulatory requirements. Since manufacturing conditions vary depending on process parameters, sterilization methods, buffer compositions, and product formulations, validation requirements often differ for each application. Consequently, manufacturers must invest significant time and financial resources to evaluate disposable components before they are incorporated into production processes.

In addition, evolving regulatory expectations from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other international regulatory authorities require continuous documentation and risk assessment throughout the product lifecycle. These regulatory requirements may increase development timelines and delay commercialization of new manufacturing processes. Although suppliers continue to develop high-quality materials with improved chemical resistance and lower extractable profiles, regulatory qualification remains a critical consideration for biopharmaceutical manufacturers.

The need for extensive validation, coupled with concerns regarding long-term material compatibility and process reliability, continues to limit rapid adoption of single-use technologies in certain high-value biologics and advanced therapy manufacturing applications, thereby restraining overall market growth.

MARKET OPPORTUNITIES

Growing Adoption of Continuous Bioprocessing Creating New Growth Opportunities

The increasing adoption of continuous bioprocessing presents a significant growth opportunity for the global market. Biopharmaceutical manufacturers are increasingly transitioning from traditional batch-based production to continuous manufacturing processes to improve productivity, reduce manufacturing costs, and achieve greater operational flexibility.

Continuous bioprocessing enables uninterrupted production while improving product consistency, reducing facility footprint, and maximizing equipment utilization. Single-use technologies play a critical role in supporting this manufacturing approach by providing flexible, closed, and contamination-free processing systems that can be rapidly deployed and easily integrated into continuous production workflows. Also, due to substantial market opportunity, market players are focusing on the introduction of new products, eventually boosting their adoption.

• For instance, in August 2023, Sartorius and Repligen Corporation launched an integrated system combining the BIOSTAT STR single-use bioreactor with XCell ATF technology, enabling continuous perfusion processing and improving upstream manufacturing efficiency for biologics production.
• Also, in May 2025, Merck KGaA launched the Ultimus Single-Use Process Container platform, supporting continuous bioprocessing through improved sterile fluid management, enhanced manufacturing flexibility, and streamlined biologics production workflows.

The growing commercialization of biologics, biosimilars, monoclonal antibodies, and advanced therapies is further accelerating investments in continuous bioprocessing infrastructure across pharmaceutical companies and CDMOs. Manufacturers are adopting integrated single-use platforms to improve process intensification, shorten production timelines, and enable faster scale-up from clinical to commercial manufacturing.

MARKET CHALLENGES

High Dependence on Disposable Consumables and Supply Chain Vulnerability to Restrain Market Growth

The global market remains highly dependent on the uninterrupted availability of disposable consumables and specialized raw materials, making supply chain resilience a significant challenge for manufacturers. Single-use bioprocessing systems require a continuous supply of disposable bioreactor bags, tubing assemblies, filters, connectors, sampling systems, fluid management components, and sterile storage containers. These products are manufactured using specialized medical-grade polymers and engineered materials that must meet stringent quality and regulatory standards. Any disruption in the availability of these materials or delays in manufacturing can directly impact biopharmaceutical production schedules.

The COVID-19 pandemic highlighted vulnerabilities in the global supply chain, as unprecedented demand for single-use technologies led to extended lead times, raw material shortages, transportation disruptions, and increased procurement costs. Although supply chain conditions have improved, many manufacturers continue to rely on a limited number of qualified suppliers for critical single-use components. As disposable assemblies are highly customized and process-specific, replacing approved suppliers often requires additional validation, compatibility testing, and regulatory documentation, making supplier diversification challenging.

Fluctuations in raw material prices, geopolitical uncertainties, international trade restrictions, and logistics disruptions can significantly influence production costs and product availability. Biopharmaceutical manufacturers increasingly recognize supply chain security as a strategic consideration when selecting single-use technologies, leading many organizations to maintain higher inventory levels and establish dual-sourcing strategies.

At the same time, suppliers are investing in regional manufacturing facilities and expanding production capacity to improve supply reliability. However, establishing new cleanroom manufacturing operations requires significant capital investment and lengthy qualification processes. As global biologics manufacturing capacity continues to expand, maintaining a stable supply of high-quality disposable components will remain essential for uninterrupted production. Consequently, continued dependence on specialized consumables, combined with supply chain uncertainties and raw material availability, remains a significant restraint that could influence the pace of adoption of single-use technologies across the global biopharmaceutical manufacturing industry.

Segmentation Analysis

By Product Type

Consumables Led Market Due to Rising Demand for Disposable Components

Based on product type, the market is segmented into equipment & systems and consumables. Additionally, equipment & systems are further segmented into single-use bioreactors, chromatography systems, single-use mixers, single-use containers, single-use sensors & analytics, and others. Moreover, consumables are further segmented into connectors, tubing, filters, cartridges, pumps, and others.

The consumables segment accounted for the largest single-use technology for biopharmaceuticals market share in 2025. The segment's dominance is primarily attributed to the recurring demand for disposable components, including bioprocess bags, tubing assemblies, filters, connectors, sampling systems, sensors, and single-use fluid transfer assemblies used throughout upstream and downstream bioprocessing. In addition, the rapid expansion of biologics, biosimilars, vaccines, monoclonal antibodies, and cell and gene therapy manufacturing has significantly increased the adoption of disposable consumables owing to their ability to minimize cross-contamination, eliminate cleaning validation, and improve manufacturing flexibility.

The equipment & systems segment is projected to grow at a CAGR of 9.0% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Workflow

Technological Advancements in Upstream Processing Led to Its Dominance

By workflow, the market is classified into upstream processing, downstream processing, and ancillary operations. Furthermore, ancillary operations are further classified into formulation, fill-finish support, storage & transfer, sampling, and media & buffer preparation.

The upstream processing segment accounted for the largest market share in 2025. The segment's dominance is primarily attributed to the extensive adoption of single-use technologies during cell culture development, media preparation, inoculum expansion, and bioreactor operations, where sterility and process flexibility are critical. In addition, the focus on market players to introduce new products coupled with technological advancements is also projected to have a positive impact on segment growth. Moreover, the segment is projected to hold a 40.2% share in 2026.

The downstream processing segment is estimated to grow at a CAGR of 9.9% during the forecast period.

By Biopharmaceutical Modality

Increasing Need for Reliable & Contamination-free Manufacturing Platforms Boosted Conventional Biopharmaceuticals Segment Growth

By biopharmaceutical modality, the market is classified into conventional biopharmaceuticals, regenerative medicine/advanced therapies, and others. The conventional biopharmaceuticals segment is further classified into monoclonal antibodies, recombinant proteins, vaccines, biosimilars, plasma-derived/specialty biologics, and others. Additionally, regenerative medicine/advanced therapies are further segmented into iPS cell-based therapies, mRNA-based products, somatic cell therapies, CAR-T cell therapies, gene therapies, and others. Also, others are further split into diagnostics, research-use biologics, process development applications, and others.

Conventional biopharmaceuticals accounted for the largest market share in 2025, as they require reliable, scalable, and contamination-free manufacturing platforms. Also, increasing investments by manufacturers to boost production are expected to have a positive impact on the segment growth during the forecast period. Moreover, the segment is projected to hold an 80.1% share in 2026.

The regenerative medicine/advanced therapies segment is estimated to grow at a CAGR of 10.1% during the forecast period.

By Scale

Rising Focus on Enhancing Manufacturing Flexibility Boosted Commercial Segment Growth

By scale, the market is classified into clinical and commercial.

The commercial segment accounted for the largest market share in 2025. The segment's dominance is primarily driven by the increasing commercial production of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and other biologics. In addition, commercial manufacturing facilities are increasingly adopting single-use bioreactors, mixing systems, filtration units, chromatography assemblies, and fluid management solutions to improve manufacturing flexibility while reducing cleaning validation, turnaround time, and operational costs. Moreover, the segment is projected to hold a 44.4% share in 2026.

The clinical segment is estimated to grow at a CAGR of 9.6% during the forecast period.

By End User

Pharmaceutical & Biopharmaceutical Companies Dominated Market Due to Large-scale In-house Manufacturing of Conventional Biopharmaceuticals

On the basis of end user, the market is classified into pharmaceutical & biopharmaceutical companies, CDMOs & CROs, academic & research institutes, and others.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest market share in 2025. The segment’s dominance is mainly driven by large-scale in-house manufacturing of conventional biopharmaceuticals. The segment’s leadership is driven by an established pharmaceutical base and increasing production of biologics. Furthermore, the segment is set to hold a 53.5% share in 2026.

The CDMOs & CROs segment is projected to grow at a CAGR of 9.9% during the forecast period.

Single-use Technology for Biopharmaceuticals Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest revenue share in 2024, at USD 7.35 billion, and was valued at USD 7.92 billion in 2025. North America is expected to remain the largest market due to its strong base of biologics manufacturers, CDMOs, clinical-stage biotech companies, and advanced therapy developers. Market growth is driven by increasing demand for high-purity biologics, antibody-drug conjugates, viral vectors, and cell and gene therapies, which require advanced purification and filtration processes.

U.S. Single-use Technology for Biopharmaceuticals Market

In 2026, the U.S. market is expected to represent USD 7.67 billion, capturing 38.3% of total global revenues.

Europe

Europe is expected to grow at a CAGR of 8.7% in the coming years, the second-highest globally, reaching USD 5.45 billion in 2026. The market is growing steadily due to its established biologics, biosimilar, vaccine, and advanced therapy manufacturing infrastructure. Countries such as Germany, the U.K., France, Italy, Spain, Switzerland, and the Nordic countries have a strong presence of biopharmaceutical companies and CDMOs, which supports continued demand for single-use systems and recurring consumables.

U.K. Single-use Technology for Biopharmaceuticals Market

The U.K. market is projected to reach USD 0.80 billion in 2026, accounting for 4.0% of global revenues.

Germany Single-use Technology for Biopharmaceuticals Market

The market in Germany is expected to reach about USD 1.24 billion in 2026, representing roughly 6.2% of global revenues.

Asia Pacific

In 2026, the Asia Pacific market is predicted to be valued at USD 4.90 billion, ranking as the third-largest globally. Asia Pacific is expected to register the fastest growth in the coming years due to rapid expansion of biopharmaceutical manufacturing capacity in China, India, Japan, South Korea, Singapore, and Southeast Asia. The region is witnessing increasing investment in biologics, biosimilars, vaccines, mRNA platforms, viral vectors, and CDMO facilities.

Japan Single-use Technology for Biopharmaceuticals Market

The market in Japan is projected to generate approximately USD 1.05 billion in revenue in 2026, representing roughly 5.2% of global revenues.

China Single-use Technology for Biopharmaceuticals Market

The market in China is expected to reach approximately USD 1.61 billion in 2026, representing roughly 8.0% of global revenues.

India Single-use Technology for Biopharmaceuticals Market

The market in India is expected to reach approximately USD 0.54 billion in 2026, representing roughly 2.7% of global revenues.

Latin America and Middle East & Africa

Both Latin America and the Middle East & Africa are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.68 billion in 2026, supported by increasing biologics and vaccine manufacturing activities in countries such as Brazil and Mexico. Regional manufacturers and public health institutions are gradually adopting single-use technologies to improve manufacturing flexibility, reduce contamination risks, and support localized production of biologics and vaccines. The Middle East & Africa market is growing from a smaller base, driven by increasing focus on healthcare localization, vaccine self-sufficiency, and biopharmaceutical manufacturing development. GCC countries are investing in local manufacturing capabilities, while selected African countries are advancing vaccine and biologics production initiatives.

GCC Single-use Technology for Biopharmaceuticals Market

In 2026, the GCC is expected to generate approximately USD 0.20 billion, representing roughly 1.0% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Top Companies Emphasize Manufacturing Expansion & Strategic Collaborations to Reinforce Their Market Positions

The global single-use technology for biopharmaceuticals market is moderately consolidated, with the top five players accounting for a major market share in 2025. Leading companies in the market include Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, and Repligen Corporation. They continue to invest in manufacturing expansion, strategic collaborations, and advanced single-use technologies to strengthen their competitive position and address the growing demand for biologics, vaccines, and advanced therapies.

• In March 2025, ABEC introduced the Advanced Therapy Bioreactor, a next-generation single-use platform designed to improve scalability and process control for cell therapy manufacturing.

Increasing investments in biologics production, cell and gene therapies, and continuous bioprocessing technologies continue to encourage manufacturers to introduce innovative single-use solutions. Also, growing adoption of flexible manufacturing platforms and expansion of CDMO facilities are expected to support market growth over the forecast period.

LIST OF KEY SINGLE-USE TECHNOLOGY FOR BIOPHARMACEUTICAL COMPANIES PROFILED

• Thermo Fisher Scientific Inc. (U.S.)
• Sartorius AG (Germany)
• Merck KGaA (Germany)
• Danaher Corporation (Cytiva) (U.S.)
• Levitronix GmbH (Switzerland)
• SaniSure, Inc. (U.S.)
• Nordson Corporation (U.S.)
• Repligen Corporation (U.S.)
• Corning Corporation (U.S.)
• ABEC, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• January 2026: Thermo Fisher Scientific expanded its U.S. biopharmaceutical manufacturing capacity to support increasing biologics production. The investment strengthens the company's supply of single-use bioprocessing systems and enhances manufacturing capabilities for pharmaceutical and biotechnology
• June 2025: Sartorius Stedim Biotech expanded its manufacturing and R&D capacities in Aubagne, France. The expansion nearly doubled cleanroom space and added automated production lines for single-use bags, strengthening the company’s bioprocess solutions portfolio.
• April 2025: Sartorius Stedim Biotech partnered with Tulip to improve end-to-end biomanufacturing visibility and optimization. The collaboration addresses key challenges in single-use bioprocessing, including process variability, regulatory compliance, and paperless manufacturing.
• September 2024: Merck KGaA launched the Mobius ADC Reactor, a single-use solution designed to simplify antibody-drug conjugate manufacturing while improving process safety and manufacturing efficiency.
• March 2023: Thermo Fisher Scientific completed the integration of CorEvitas, enhancing its biopharmaceutical development capabilities by combining real-world evidence with end-to-end biologics development and manufacturing services.

REPORT COVERAGE

The single-use technology for biopharmaceuticals market report provides an in-depth analysis of all market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation